21 October 2021 - BEAM Alliance

How the EU Pharmaceutical Strategy could help prevent the next pandemic

Video recordings of BEAM’s Roundtable. Discussion with EC officials and experts on the AMR initiatives of the EU Pharmaceutical Strategy.

27 September 2021 - BEAM Alliance

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

BEAM Alliance welcomes the HERA proposal but urges EU Member States to recognise the importance of early-stage support for Research…

17 November 2021 - BEAM Alliance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

BEAM News
Member News
Events

Latest news of BEAM Alliance

25 November 2021 - BEAM Alliance

Antimicrobial Resistance Campaign 2021

Antimicrobial Resistance Campaign 2021. The needs of SMEs must be considered when reshaping the regulatory framework in AMR innovation.

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

17 November 2021 - BEAM Alliance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

21 October 2021 - BEAM Alliance

How the EU Pharmaceutical Strategy could help prevent the next pandemic

Video recordings of BEAM’s Roundtable. Discussion with EC officials and experts on the AMR initiatives of the EU Pharmaceutical Strategy.

27 September 2021 - BEAM Alliance

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

BEAM Alliance welcomes the HERA proposal but urges EU Member States to recognise the importance of early-stage support for Research…

07 September 2021 - BEAM Alliance

Antimicrobial resistance: the silent pandemic

It is necessary to support R&D with ad hoc funding (so-called PUSH incentives), but above all to set up market…

page 1/5

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

02 December 2021 - Infex Therapeutics Ltd

Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains

Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains. Infex Therapeutics is part of iiCON,…

03 November 2021 - BioVersys AG

BioVersys announces first subjects dosed in additional phase 1 clinical trials of BV100

BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for…

01 November 2021 - Infex Therapeutics Ltd

Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics

Infex is building a new clinical pipeline of innovative drugs to treat pandemic infections and is creating a portfolio of…

04 October 2021 - Nabriva Therapeutics GmbH

Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)

XENLETA® (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

22 September 2021 - NovaBiotics Ltd

NovaBiotics publishes further data on the mechanism of action of its candidate NM001 therapy (Lynovex) for cystic fibrosis (CF)

NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on leveraging its novel immunology platforms to design and develop first-in-class…

10 September 2021 - AdjuTec Pharma AS

AdjuTec Pharma Strengthens the Patent Portfolio

AdjuTec Pharma is a Company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market.…

page 1/32

Events

07 April 2022

6th AMR Conference

The AMRconference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and the…

26 January 2022

Human – Animal One Health: At the Confluence of human & veterinary public health

«The One Health Concept: At the confluence of human and veterinary public health» aims to bring together researchers, industrial stakeholders and…

10 January 2022

Biotech Showcase 2022 (In-person & Virtual Event)

Engage with Global investors & Life Sciences Executives! Join us from January 10–12, 2022 in San Francisco, or Join us…

09 December 2021

SCT Virtual Symposium: On the hunt for next generation antimicrobial agents

An exciting two-day symposium entitled: On the hunt for next generation antimicrobial agents. This symposium will bring together some of…

23 November 2021

Phage futures Europe: Translating phage-based applications into clinically and commercially viable therapeutics

Seeing the news that Proteon Pharmaceuticals secured a €21 million investment was an exciting moment. It is another backing in…

19 November 2021

REVIVE Webinar: The roles of different actors in developing new treatments for drug-resistant infections

This World Antimicrobial Awareness Week, GARDP, together with WHO, will be holding an AMR Discussions webinar in which a panel…

17 November 2021

6th Annual Microbiome Connect: Gut Therapeutics

This event is a unique gathering of individuals from academia and industry who are collaborating to advance microbiome science.

15 November 2021

3rd SCI-RSC symposium on antimicrobial drug discovery

Coinciding with WHO’s World Antibiotics Awareness week, this two-day meeting will examine the latest advances in antimicrobial drug discovery from…

25 October 2021

BIO-Europe® 2021 Digital – 27th Annual International Partnering Conference

The international BIO-Europe® 2021 gathering will be held digitally, providing certainty, in this time of insecurity, to execute its pivotal…

page 1/12

Latest news of BEAM Alliance

Antimicrobial Resistance Campaign 2021

AMR: The life of innovative SMEs

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

How the EU Pharmaceutical Strategy could help prevent the next pandemic

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

Antimicrobial resistance: ​the silent pandemic

Latest news of BEAM Members

Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains

BioVersys announces first subjects dosed in additional phase 1 clinical trials of BV100

Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics

Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)

NovaBiotics publishes further data on the mechanism of action of its candidate NM001 therapy (Lynovex) for cystic fibrosis (CF)

AdjuTec Pharma Strengthens the Patent Portfolio

Events

6th AMR Conference

Human – Animal One Health: At the Confluence of human & veterinary public health

Biotech Showcase 2022 (In-person & Virtual Event)

SCT Virtual Symposium: On the hunt for next generation antimicrobial agents

Phage futures Europe: Translating phage-based applications into clinically and commercially viable therapeutics

REVIVE Webinar: The roles of different actors in developing new treatments for drug-resistant infections

6th Annual Microbiome Connect: Gut Therapeutics

3rd SCI-RSC symposium on antimicrobial drug discovery

BIO-Europe® 2021 Digital – 27th Annual International Partnering Conference

Antimicrobial resistance: the silent pandemic